REPORT FROM AAN – BOSTON, MA, APRIL 22-28, 2017 – The following summarizes data from key studies presented at the American Academy of Neurology annual meeting on the long-term use of disease-modifying therapies in multiple sclerosis. Read More

The U.S. Food and Drug Administration has approved ocrelizumab (Ocrevus) for the treatment of adult patients with relapsing forms of multiple sclerosis, and for primary-progressive MS. Ocrelizumab is a humanized monoclonal antibody that targets CD20+ B cells. It is the first disease-modifying therapy to be approved for PPMS. The FDA had given ocrelizumab breakthrough therapy and fast track designations, and granted it a priority review. Read More